Imaging with [99m]Tc-Maraciclatide Correlates with Identification of Early-Stage Endometriosis by Laparoscopic Surgery

15 Mar 2024
www.prnewswire.com
LONDON, March 15, 2024 /PRNewswire/ -- Serac Healthcare Limited ("Serac Healthcare" or "the Company"), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, and the Nuffield Department of Women's and Reproductive Health at the University of Oxford announce that preliminary data has been presented from the "Detecting Endometriosis expressed integrins using technetium-99m" (DETECT) imaging study, indicating that 99mTc-maraciclatide is capable of imaging superficial peritoneal endometriosis, the earliest stage of the disease. The data was presented today by Dr Tatjana Gibbons, an investigator on the study from the University of Oxford, in an oral presentation at the Society for Reproductive Investigation (SRI) annual meeting taking place from 12-16 March 2024 in Vancouver, Canada.
Imaging with [99m]Tc-Maraciclatide Correlates with Identification of Early-Stage Endometriosis by Laparoscopic Surgery
Preview
Source: PRNewswire
Imaging with [99m]Tc-Maraciclatide Correlates with Identification of Early-Stage Endometriosis by Laparoscopic Surgery
Preview
Source: PRNewswire
Nuffield Department of Women's & Reproductive Health at the University of Oxford Logo
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.